A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 5, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2028

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Atezolizumab

Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1.

DRUG

Bevacizumab

Bevacizumab will be administered at a dose of 15 mg/kg by IV infusion on Day 1.

DRUG

Tiragolumab

Tiragolumab will be administered at a dose of 600 mg by IV infusion on Day 1.

DRUG

Tobemstomig

Tobemstomig will be administered at a dose of 600 mg by IV infusion on Day 1

Trial Locations (33)

112

Taipei Veterans General Hospital, Taipei

1023

Auckland District Health Board (ADHB), Auckland

1100

Wiener Gesundheitsverbund, Klinik Favoriten, Vienna

1180

Department of Internal Medicine III AKH and Medical University of Vienna, Vienna

8036

Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona

9020

Klinikum Klagenfurt am Wörthersee, Klagenfurt

10032

Columbia University Medical Center, New York

10051

National Taiwan University Hospital (NTUH) - Cancer Research Center, Zhongzheng Dist.

13496

CHA Bundang Medical Center, Gyeonggi-do

20007

Georgetown University Medical Center, Washington D.C.

21079

Centre Georges Francois Leclerc (CGFL), Dijon

28040

Hospital Universitario Fundacion Jimenez Diaz., Madrid

31620

Clínica Universidad de Navarra, Pamplona

35042

Centre Eugene Marquis (CEM), Rennes

39008

Hospital Universitario Marques de Valdecilla, Santander

40705

Taichung Veterans General Hospital, Taichung

45147

University Essen, Essen

55131

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz

60596

Universitaets Klinikum Frankfurt - Zentrum der Inneren Medizin, Frankfurt

70457

National Cheng Kung University Hospital, Tainan City

83301

Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital, Tainan City

90033

University of Southern California (USC), Los Angeles

94800

Assistance Publique-Hopitaux de Paris, Villejuif

Gustave Roussy, Villejuif

90404-2023

University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica

48201-2013

Barbara Ann Karmanos Cancer Institute - Karmanos Cancer Center - Main Campus, Detroit

75390-8813

UT Southwestern Medical Center, Dallas

98109-4433

Fred Hutchinson/University of Washington Cancer Consortium, Seattle

003-722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

135-710

Samsung Medical Center, Seoul

BT9 7AB

Belfast Health and Social Care Trust - Belfast City Hospital, Belfast

Unknown

Imperial College London - Imperial Centre for Translational and Experimental Medicine (ICTEM), London

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT05908786 - A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter